首页> 外文期刊>European journal of pharmaceutics and biopharmaceutics: official journal of Arbeitsgemeinschaft fuer Pharmazeutische Verfahrenstechnik e.V >An investigation into the use of polymer blends to improve the printability of and regulate drug release from pharmaceutical solid dispersions prepared via fused deposition modeling (FDM) 3D printing
【24h】

An investigation into the use of polymer blends to improve the printability of and regulate drug release from pharmaceutical solid dispersions prepared via fused deposition modeling (FDM) 3D printing

机译:将聚合物共混物的使用研究改善通过熔融沉积建模(FDM)3D印刷制备的药物固体分散体的可印刷性和调节药物释放

获取原文
获取原文并翻译 | 示例
           

摘要

FDM 3D printing has been recently attracted increasing research efforts towards the production of personalized solid oral formulations. However, commercially available FDM printers are extremely limited with regards to the materials that can be processed to few types of thermoplastic polymers, which often may not be pharmaceutically approved materials nor ideal for optimizing dosage form performance of poor soluble compounds. This study explored the use of polymer blends as a formulation strategy to overcome this processability issue and to provide adjustable drug release rates from the printed dispersions. Solid dispersions of felodipine, the model drug, were successfully fabricated using FDM 3D printing with polymer blends of PEG, PEO and Tween 80 with either Eudragit E PO or Soluplus. As PVA is one of most widely used polymers in FDM 3D printing, a PVA based solid dispersion was used as a benchmark to compare the polymer blend systems to in terms of processability. The polymer blends exhibited excellent printability and were suitable for processing using a commercially available FDM 3D printer. With 10% drug loading, all characterization data indicated that the model drug was molecularly dispersed in the matrices. During in vitro dissolution testing, it was dear that the disintegration behavior of the formulations significantly influenced the rates of drug release. Eudragit EPO based blend dispersions showed bulk disintegration; whereas the Soluplus based blends showed the 'peeling' style disintegration of strip-by strip. The results indicated that interplay of the miscibility between excipients in the blends, the solubility of the materials in the dissolution media and the degree of fusion between the printed strips during FDM process can be used to manipulate the drug release rate of the dispersions. This brings new insight into the design principles of controlled release formulations using FDM 3D printing. (C) 2016 Elsevier B.V. All rights reserved.
机译:最近,FDM 3D印刷已经吸引了越来越多的研究旨在生产个性化固体口服配方的研究。然而,商业上可获得的FDM打印机对可以处理的材料非常有限,这些材料可以处理少量的热塑性聚合物,这通常可能不是药学批准的材料,也不适用于优化可差的可溶性化合物的剂型性能。本研究探讨了聚合物共混物作为制剂策略,以克服这种可加工性问题,并提供来自印刷分散体的可调节药物释放速率。使用FDM 3D印刷成功制造Felodipine的固体分散体,使用FDM 3D印刷与PEG,PEO和TWEEN 80的聚合物共混物,其中Eudragit E Po或Soluplus。由于PVA是FDM 3D打印中最广泛使用的聚合物之一,因此使用PVA的固体分散体作为基准,以将聚合物混合系统与加工性进行比较。聚合物共混物表现出优异的印刷性,并且适合于使用市售的FDM 3D打印机加工。含有10%的药物负载,所有表征数据表明模型药物分散在基质中。在体外溶出试验期间,亲爱的制剂的崩解行为是显着影响了药物释放的率。基于Eudragit基于EPO的混合分散体显示散装崩解;虽然Soluplus的混合物显示了条带条带的“剥离”风格崩解。结果表明,共混物中赋形剂之间的混合物的相互作用,在FDM工艺期间,溶解介质中材料在溶解介质中的溶解度和印刷条之间的融合程度可用于操纵分散体的药物释放速率。这为使用FDM 3D打印进行了新的洞察控制释放配方的设计原则。 (c)2016年Elsevier B.v.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号